HRP20110892T1 - Policiklični derivati indazola koji su inhibitori erk - Google Patents

Policiklični derivati indazola koji su inhibitori erk Download PDF

Info

Publication number
HRP20110892T1
HRP20110892T1 HR20110892T HRP20110892T HRP20110892T1 HR P20110892 T1 HRP20110892 T1 HR P20110892T1 HR 20110892 T HR20110892 T HR 20110892T HR P20110892 T HRP20110892 T HR P20110892T HR P20110892 T1 HRP20110892 T1 HR P20110892T1
Authority
HR
Croatia
Prior art keywords
substituted
group
image
pharmaceutically acceptable
alkyl
Prior art date
Application number
HR20110892T
Other languages
English (en)
Croatian (hr)
Inventor
Cooper Alan
Deng Yongqi
W. Jr. Shipps Gerald
Shih Neng-Yang
Zhu Hugh
Sun Robert
Kelly Joseph
Doll Ronald
Nan Yang
Wang Tong
Desai Jagdish
Wang James
Dong Youhao
S. Madison Vincent
Xiao Li
Hruza Alan
Arshad Siddiqui M.
Samatar Ahmed
Paliwal Sunil
Tsui Hon-Chung
A. Celebi Azim
Wu Yiji
Babu Boga Sobhana
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HRP20110892T1 publication Critical patent/HRP20110892T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HR20110892T 2005-12-13 2006-12-11 Policiklični derivati indazola koji su inhibitori erk HRP20110892T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74985605P 2005-12-13 2005-12-13
PCT/US2006/046959 WO2007070398A1 (fr) 2005-12-13 2006-12-11 Derives polycycliques d'indazole inhibiteurs des erk

Publications (1)

Publication Number Publication Date
HRP20110892T1 true HRP20110892T1 (hr) 2011-12-31

Family

ID=37969564

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110892T HRP20110892T1 (hr) 2005-12-13 2006-12-11 Policiklični derivati indazola koji su inhibitori erk

Country Status (28)

Country Link
US (1) US20070191604A1 (fr)
EP (1) EP1966151B1 (fr)
JP (1) JP4881957B2 (fr)
KR (1) KR101417136B1 (fr)
CN (1) CN101370784B (fr)
AR (1) AR056891A1 (fr)
AT (1) ATE527240T1 (fr)
AU (1) AU2006326616B2 (fr)
BR (1) BRPI0619823B8 (fr)
CA (1) CA2633023C (fr)
CY (1) CY1112760T1 (fr)
DK (1) DK1966151T3 (fr)
EC (1) ECSP088550A (fr)
ES (1) ES2372976T3 (fr)
HR (1) HRP20110892T1 (fr)
IL (1) IL192034A (fr)
MY (1) MY149430A (fr)
NO (1) NO341831B1 (fr)
NZ (1) NZ569087A (fr)
PE (2) PE20100562A1 (fr)
PL (1) PL1966151T3 (fr)
PT (1) PT1966151E (fr)
RS (1) RS51981B (fr)
RU (1) RU2442778C9 (fr)
SI (1) SI1966151T1 (fr)
TW (1) TWI344466B (fr)
WO (1) WO2007070398A1 (fr)
ZA (1) ZA200805525B (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
WO2015041533A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
WO2015156674A2 (fr) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Méthode de traitement du cancer
WO2015178770A1 (fr) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer
WO2017058007A1 (fr) 2015-10-01 2017-04-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inhibiteurs de l'histone désacétylase utilisables dans le traitement d'un mélanome résistant aux médicaments
WO2017099591A1 (fr) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Traitement de cancers à mutation braf résistants aux inhibiteurs
WO2017204626A1 (fr) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Polythérapie combinant map2k4/map3k1 et une inhibition de mek/erk

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
EP1984331B1 (fr) * 2006-02-16 2010-10-20 Schering Corporation Dérivés de pyrrolidine comme inhibiteurs de la erk
CA2656398A1 (fr) 2006-06-30 2008-01-10 Schering Corporation Piperidines substituees qui augmentent l'activite p53 et leurs utilisations
AR068046A1 (es) * 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
WO2009073513A1 (fr) * 2007-11-30 2009-06-11 Schering Corporation Biomarqueurs braf
RU2525389C2 (ru) 2008-02-21 2014-08-10 Мерк Шарп И Доум Корп. Соединения, которые являются ингибиторами erk
EP2265610B1 (fr) 2008-02-29 2012-12-12 Array Biopharma, Inc. Inhibiteurs de raf de pyrazole[3,4-b]pyridine
US20110278332A1 (en) * 2009-03-26 2011-11-17 Protexer, Inc. Shoe cover removal apparatus
US8637554B2 (en) * 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2010021978A2 (fr) * 2008-08-19 2010-02-25 Schering Corporation Marqueur biologique à base d'il-8
EP2448942B1 (fr) 2009-07-02 2014-09-24 Merck Sharp & Dohme Corp. COMPOSÉS TRICYCLIQUES CONDENSÉS COMME INHIBITEURS DE mTOR
JP2013506669A (ja) * 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
WO2011123937A1 (fr) * 2010-04-06 2011-10-13 University Health Network Inhibiteurs de kinases et procédé de traitement du cancer utilisant ceux-ci
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) * 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9090593B2 (en) 2010-12-09 2015-07-28 Amgen Inc. Bicyclic compounds as Pim inhibitors
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
CA2830780A1 (fr) 2011-03-22 2012-09-27 Amgen Inc. Composes d'azole utilises en tant qu'inhibiteurs des pim
EP2699567A1 (fr) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
WO2013016164A1 (fr) 2011-07-26 2013-01-31 Merck Sharp & Dohme Corp. Composés tricycliques fusionnés comme inhibiteurs de mtor
WO2013062923A1 (fr) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Macrocycles augmentant l'activité p53 et leurs utilisations
US9062071B2 (en) 2011-12-21 2015-06-23 Merck Sharp & Dohme Corp. Substituted piperidines as HDM2 inhibitors
ITMI20120135A1 (it) * 2012-02-02 2013-08-03 Diab Int Ab Procedimento per la produzione di schiume di pet e schiume di pet ottenute con questo procedimento
WO2013169858A1 (fr) 2012-05-08 2013-11-14 The Broad Institute, Inc. Méthodes de diagnostic et de traitement chez des patients ayant ou présentant un risque de développer une résistance à une thérapie anticancéreuse
CN103450163B (zh) * 2012-05-29 2017-06-23 中国医学科学院药物研究所 吲唑类化合物、其制备方法及其药物用途
AU2013318283A1 (en) 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
KR20150060724A (ko) * 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
EP2935263B1 (fr) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs d'hdm2
LT3063143T (lt) 2013-11-01 2018-08-10 Novartis Ag Aminoheteroarilbenzamidai, kaip kinazės inhibitoriai
WO2016095088A1 (fr) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Inhibiteurs d'erk
WO2016095089A1 (fr) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Inhibiteurs d'erk
US10457669B2 (en) 2015-10-21 2019-10-29 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
PL3426637T3 (pl) * 2016-03-11 2022-05-30 Angel Pharmaceutical Co., Ltd. Związki i sposoby modulowania kinazy tyrozynowej brutona
US10934304B2 (en) * 2016-10-05 2021-03-02 Recurium Ip Holdings, Llc Spirocyclic compounds
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
CN114605329B (zh) * 2022-03-28 2024-01-26 河南中医药大学 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
IL145757A (en) * 2000-02-05 2007-12-03 Vertex Pharma History of pyrazole and pharmaceutical preparations containing them
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
KR101166745B1 (ko) * 2002-09-05 2012-07-23 아방티 파르마 소시에테 아노님 의약으로서의 신규한 아미노인다졸 유도체 및 이를 함유하는 약제학적 조성물

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
WO2015041533A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
WO2015156674A2 (fr) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Méthode de traitement du cancer
WO2015178770A1 (fr) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer
WO2017058007A1 (fr) 2015-10-01 2017-04-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inhibiteurs de l'histone désacétylase utilisables dans le traitement d'un mélanome résistant aux médicaments
WO2017099591A1 (fr) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Traitement de cancers à mutation braf résistants aux inhibiteurs
WO2017204626A1 (fr) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Polythérapie combinant map2k4/map3k1 et une inhibition de mek/erk

Also Published As

Publication number Publication date
ES2372976T3 (es) 2012-01-30
MY149430A (en) 2013-08-30
DK1966151T3 (da) 2012-01-30
PL1966151T3 (pl) 2012-02-29
AR056891A1 (es) 2007-10-31
CN101370784B (zh) 2012-10-10
ZA200805525B (en) 2009-11-25
BRPI0619823A8 (pt) 2019-01-22
EP1966151B1 (fr) 2011-10-05
TWI344466B (en) 2011-07-01
NZ569087A (en) 2011-09-30
EP1966151A1 (fr) 2008-09-10
IL192034A0 (en) 2008-12-29
NO341831B1 (no) 2018-01-29
CA2633023C (fr) 2015-11-24
PT1966151E (pt) 2011-12-20
NO20083114L (no) 2008-09-12
ATE527240T1 (de) 2011-10-15
CA2633023A1 (fr) 2007-06-21
ECSP088550A (es) 2008-07-30
BRPI0619823B8 (pt) 2021-05-25
AU2006326616B2 (en) 2012-09-06
RU2442778C2 (ru) 2012-02-20
WO2007070398A1 (fr) 2007-06-21
TW200732324A (en) 2007-09-01
BRPI0619823A2 (pt) 2011-11-08
JP2009519338A (ja) 2009-05-14
CY1112760T1 (el) 2016-02-10
US20070191604A1 (en) 2007-08-16
IL192034A (en) 2014-08-31
BRPI0619823B1 (pt) 2020-11-17
AU2006326616A1 (en) 2007-06-21
PE20100562A1 (es) 2010-08-20
CN101370784A (zh) 2009-02-18
JP4881957B2 (ja) 2012-02-22
KR20080085018A (ko) 2008-09-22
PE20071095A1 (es) 2007-11-19
KR101417136B1 (ko) 2014-08-07
RU2442778C9 (ru) 2012-08-10
HK1114851A1 (en) 2008-11-14
SI1966151T1 (sl) 2012-02-29
RU2008128119A (ru) 2010-01-20
RS51981B (sr) 2012-02-29

Similar Documents

Publication Publication Date Title
AR130796A1 (es) Compuestos triheterocíclicos novedosos
ES2558777T3 (es) (R)-(E)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1H-indazol-3-il)vinil)-1H-pirazol-1-il)etanol cristalino y su uso como inhibidor de FGFR
JP5997252B2 (ja) プロテインキナーゼ阻害剤
CN105294736B (zh) Cdk类小分子抑制剂的化合物及其用途
RU2010138635A (ru) Соединения, которые являются ингибиторами erk
RU2009148867A (ru) Полициклические производные индазола и их применение в качестве ингибиторов erk для лечения рака
EP2076128A2 (fr) Inhibiteurs de la protéine kinase et procédés pour utiliser ceux-ci
ES2576497T3 (es) Compuesto de piperidina novedoso o sal del mismo
HRP20150825T1 (hr) Imidazo[1,2,-a]piridinski derivati kao inhibitori fgfr kinaze za uporabu u terapiji
EA200800478A1 (ru) Макроциклические ингибиторы вируса гепатита с
RU2008128119A (ru) Новые соединения, действующие как ингибиторы erk
ME02125B (fr) Inhibiteurs d'iap
ES2914072T3 (es) Sal de derivado de piridina monocíclico y su cristal
ME01318B (fr) Inhibiteurs macrocycliques du virus de l'hépatite c
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
BR112012015248B1 (pt) Composto
HRP20151410T1 (hr) Derivati pikolinamida kao inhibitori kinaze
CA3181354A1 (fr) Antagonistes du recepteur a2a de l'adenosine
HRP20140516T1 (hr) Farmaceutski spojevi
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
BRPI0519288A2 (pt) compostos heterocÍclicos como antagonistas de ccr2b
AR046170A1 (es) Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b
WO2020070332A1 (fr) Composés d'oxindole destinés à être utilisés en tant qu'inhibiteurs de map4k1
KR20170036095A (ko) Smac 모방체로서의 6-알키닐 피리딘 유도체
WO2020073031A1 (fr) Hétérocycles bicycliques fusionnés en tant qu'agents thérapeutiques